Sen. Collins, Colleagues Urge FDA to Study Long-Term Health Impacts of COVID-19
November 09, 2021
November 09, 2021
WASHINGTON, Nov. 9 -- Sen. Susan M. Collins, R-Maine, issued the following news release:
U.S. Senator Susan Collins (R-ME), a member of the Senate Health Committee, joined a bipartisan group of her colleagues in sending a letter to the Food and Drug Administration (FDA) urging the agency to study the long-term effects of COVID-19 and potential treatments for those suffering from long-haul COVID-19.
"As we continue to battle the COVID-19 pandemic, it is clear there . . .
U.S. Senator Susan Collins (R-ME), a member of the Senate Health Committee, joined a bipartisan group of her colleagues in sending a letter to the Food and Drug Administration (FDA) urging the agency to study the long-term effects of COVID-19 and potential treatments for those suffering from long-haul COVID-19.
"As we continue to battle the COVID-19 pandemic, it is clear there . . .